Jan 8, 2002
Dr. Dieterich, I have heard of a new antiretroviral drug being tested. Its name is ACH443. I was diagnosed one year ago with Hep B as a Chronic Carrier. My liver bipsy didn't show damages at that time. My ALT is 226 and AST is 100. I don't want to rush into a trial based on financial restrictions. I could probably afford Interferon, but I am concerned about side effects, but the idea of having something like 33 of chances to get cured after 4 months makes it a good option, better than Epivir (1 year) that besides the risk of having some kind of mutant virus may be out of my budget. I don't have health insurance. What would be your advice? Thanks and congratulations for your job supporting us.
Response from Dr. Dieterich
The ACH drug is a good one and would not require any insurance. This phase of it is only a short trial, but we will guarantee that you will get on the longer version of the trial if you did the two week trial now. Please contact Debby Goldman at 212 995 6907 if you would like to volunteer. There appears to date to be no side effects. Hope to see you and anyone else who would like to participate! DTD
RE: Please clarify
Interferon/Lamivudine/Entecavir/Which one is for me?
- Red Spot On Tongue Hiv
- Will Two People Infected With Genital Herpes Make Each Others Herpes Worse?
- Will Masturbation Cause Chlamydia To Come Back?
- Will Hpv 16 And Hpv 18 Go Away On Its Own?
- What Are The Ways Can You Get Chlamydia?
- What Causes Recurring Yeast Infections And Bacteria Vaginosis?
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.